Blockchain Registration Transaction Record

Sigyn Launches CTE Initiative for Former NFL Players Using Blood Purification Tech

Sigyn Therapeutics launches initiative to evaluate CardioDialysis and other technologies for diagnosing and treating CTE in former NFL players, targeting chronic inflammation as a key disease driver.

This news matters because it addresses a critical health crisis among athletes, particularly former NFL players, who face disproportionately high risks of neurodegenerative diseases like CTE due to repetitive head trauma. The initiative represents a potential breakthrough in diagnosing and treating CTE in living patients, moving beyond post-mortem identification to active intervention. By targeting chronic inflammation—a key driver of CTE progression—Sigyn's approach could lead to earlier detection and more effective therapies, improving quality of life for athletes and potentially benefiting others with neuroinflammatory conditions. The use of blood purification technology like CardioDialysis offers a novel strategy to mitigate long-term brain damage, highlighting the intersection of sports medicine and advanced biotechnology in combating irreversible neurological disorders.